Masse-Grenier Marianne, Chang Sue-Ling, Bélanger Ariane, Stephan Jean-François, Hébert Johanne, Deschamps Pierre, Plourde Louis, Provost François, Farzin Houman, Fallu Jean-Sébastien, Dorval Michel
Faculty of Pharmacy, Université Laval, Québec City, QC, Canada.
Oncology Division, CHU de Québec-Université Laval Research Center, Québec City, QC, Canada.
Palliat Support Care. 2024 Oct;22(5):1395-1405. doi: 10.1017/S1478951524001494.
Promising studies show that psilocybin-assisted therapy relieves existential distress in patients with serious illnesses, a difficult condition to treat with current treatment options. There is growing interest in this therapy in palliative care. Canada recently amended its laws to allow physicians to request psilocybin for end-of-life distress. However, barriers to access remain. Since implementing psilocybin-assisted therapy within palliative care depends on the attitudes of healthcare providers willing to recommend it, they should be actively engaged in the broader discussion about this treatment option. We aimed (1) to identify issues and concerns regarding the acceptability of this therapy among palliative care professionals and to discuss ways of remedying them and (2) to identify factors that may facilitate access.
A qualitative study design and World Café methodology were adopted to collect data. The event was held on April 24, 2023, with 16 palliative care professionals. The data was analyzed following an inductive approach.
Although participants were interested in psilocybin-assisted therapy, several concerns and needs were identified. Educational and certified training needs, medical legalization of psilocybin, more research, refinement of therapy protocols, reflections on the type of professionals dispensing the therapy, the treatment venue, and eligibility criteria for treatment were discussed.
Palliative care professionals consider psilocybin-assisted therapy a treatment of interest, but it generates several concerns. According to our results, the acceptability of the therapy and the expansion of its access seem interrelated. The development of guidelines will be essential to encourage wider therapy deployment.
有前景的研究表明，裸盖菇素辅助疗法可缓解重症患者的存在性困扰，而这是当前治疗方案难以应对的棘手状况。在姑息治疗领域，人们对这种疗法的兴趣与日俱增。加拿大最近修订了法律，允许医生为临终困扰患者申请使用裸盖菇素。然而，获取该疗法仍存在障碍。由于在姑息治疗中实施裸盖菇素辅助疗法取决于愿意推荐它的医疗服务提供者的态度，因此他们应积极参与关于这一治疗方案的更广泛讨论。我们的目标是：（1）确定姑息治疗专业人员对该疗法可接受性的问题和担忧，并探讨解决这些问题的方法；（2）确定可能促进获取该疗法的因素。
采用定性研究设计和世界咖啡馆方法收集数据。该活动于2023年4月24日举行，有16名姑息治疗专业人员参与。数据采用归纳法进行分析。
尽管参与者对裸盖菇素辅助疗法感兴趣，但也确定了一些担忧和需求。讨论了教育和认证培训需求、裸盖菇素的医学合法化、更多研究、治疗方案的完善、对提供该疗法的专业人员类型的思考、治疗场所及治疗资格标准等问题。
姑息治疗专业人员认为裸盖菇素辅助疗法是一种值得关注的治疗方法，但它引发了一些担忧。根据我们的结果，该疗法的可接受性及其获取范围的扩大似乎相互关联。制定指导方针对于鼓励更广泛地应用该疗法至关重要。
